Trial results
$CYTK — aficamten
CYTOKINETICS INC (CYTK) aficamten: trial results in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a pediatric population, 2027.
The catalyst
"We expect to present topline data in early 2027."
— Cytokinetics, Incorporated, 8-K filed 2026-11-04 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
CYTK-AFICAMTEN-2026- Company
- CYTOKINETICS INC
- Kind
- Trial results
- Indication
- symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a pediatric population
- Window
- 2027-01-01 – 2027-04-30
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.